Detalhe da pesquisa
1.
Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia.
Cancer Sci
; 111(4): 1314-1323, 2020 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31971321
2.
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Cancer
; 126(2): 304-310, 2020 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31626339
3.
Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed/refractory paediatric B-ALL.
Br J Haematol
; 188(4): e36-e39, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31797346
4.
Long-term follow-up of blinatumomab in patients with relapsed/refractory Philadelphia chromosome-positive B-cell precursor acute lymphoblastic leukaemia: Final analysis of ALCANTARA study.
Eur J Cancer
; 146: 107-114, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33588145
5.
A phase 1b study of blinatumomab in Japanese children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Int J Hematol
; 112(2): 223-233, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32564243
6.
Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia.
Leukemia
; 34(9): 2473-2478, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32094465
7.
Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
Blood Cancer J
; 8(9): 80, 2018 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-30190453